SpectraCure AB (publ) OMXSTO:SPEC:
APPOINTS FATA MRSIC AS CFO EFFECTIVE MAY 2026, SUCCEEDING HENRIK LJUNG
Spectracure Appoints Fata Mrsic As CFO
Earlier from SpectraCure
- Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
- SPEC: Promising clinical progress, but widened losses and liquidity risks raise going concern doubts
- Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
- Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
- Spectracure Q3 Net Loss SEK 35 Mln
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure